The Evolving Therapeutic Landscape in Sjögren’s Disease: From Pathophysiology to Clinical Evidence
Objectives:
Sjögren’s disease carries a profound clinical and psychosocial burden, frequently compounded by delayed diagnosis and inadequate conventional treatments. This live symposium will explore the unmet needs and pathophysiology of Sjögren’s disease, focusing on the central role of B-cell hyperactivity and the rationale for B-cell depletion. Expert faculty will review the mechanisms of action and key clinical data for emerging targeted B-cell depleting therapies that are expanding the therapeutic landscape. Join us for an exciting and interactive discussion on this new generation of biologics that promise to shift the clinical paradigm from simple symptom management toward true disease modification.
This session is supported by an independent funding from Novartis.
Agenda:
Coming soon
